CerTest Launches VIASURE SARS-CoV-2 Variant II Real Time PCR Detection Kit
By LabMedica International staff writers Posted on 30 Jul 2021 |
Image: VIASURE SARS-CoV-2 Variant II Real Time PCR Detection Kit (Photo courtesy of CerTest Biotec)
CerTest Biotec (Zaragoza, Spain) has launched VIASURE SARS-CoV-2 Variant II Real Time PCR Detection Kit, a real-time RT-PCR test designed for the qualitative detection of RNA from genetic mutations in the S gene (P681R, L452R and E484Q) from positive SARS-CoV-2 nasopharyngeal samples.
The appearance of genetic mutations is a natural and expected event within the evolution process of a virus. In fact, some specific mutations define the viral genetic groups currently circulating globally. Besides, thanks to the genetic sequencing of the pathogen worldwide, it has been possible to establish patterns of dispersal and evolution of the virus. All viruses, including SARS-CoV-2, mutate over time. Some changes may affect the virus’s properties, such as how easily it spreads, the associated disease severity, or the performance of vaccines, therapeutic medicines, diagnostic tools, or other public health and social measures.
At the end of 2020, the appearance of variants with a higher risk prompted the characterization of Variants of Interest (VOI) and Variants of Concern (VOC), in order to facilitate epidemiological control. Some of these SARS-CoV-2 variants are Delta, Kappa and Epsilon. Delta (B.1.617.2 lineage) and Kappa (B.1.617.1 lineage) were closely associated with a huge COVID-19 increase in India during spring 2021. Delta variant has multiple mutations in the Spike protein, including P681R and L452R. Kappa variant has also genetic mutations in the Spike protein, including P681R, L452R and E484Q. Epsilon variant, first detected in California, USA, consists of two distinct lineages B.1.427 and B.1.429 in clade 20C. This variant has multiple mutations in the spike protein, including L452R. An estimated increase in transmission rate of the B.1.427/B.1.429 lineages related to circulating non- B.1.427/B.1.429 lineages was 20%.
All these variants described above show potential reduction in neutralization by some
immunotherapies and reduction of expected effects of vaccines or has been identified to cause community transmission. That is why, their appearance constitute a first-order public health problem that can have an important impact on control of the pandemic. A concern regarding the new variants is that their detection by molecular techniques (RT-PCR) could be affected.
For this reason, VIASURE SARS-CoV-2 Variant II Real Time PCR Detection Kit has been designed to allow the detection of the main mutation associated with the variant under surveillance. The test is intended for use as an aid to monitor the prevalence of genetic mutations in the S gene (P681R, L452R and E484Q) and to assist in control measures. RNA is extracted from respiratory specimens, complementary DNA (cDNA) is synthesized and amplified using RT-qPCR and detected using fluorescent reporter dye probes specific for genetic mutations in the S gene (P681R, L452R and E484Q).
The appearance of genetic mutations is a natural and expected event within the evolution process of a virus. In fact, some specific mutations define the viral genetic groups currently circulating globally. Besides, thanks to the genetic sequencing of the pathogen worldwide, it has been possible to establish patterns of dispersal and evolution of the virus. All viruses, including SARS-CoV-2, mutate over time. Some changes may affect the virus’s properties, such as how easily it spreads, the associated disease severity, or the performance of vaccines, therapeutic medicines, diagnostic tools, or other public health and social measures.
At the end of 2020, the appearance of variants with a higher risk prompted the characterization of Variants of Interest (VOI) and Variants of Concern (VOC), in order to facilitate epidemiological control. Some of these SARS-CoV-2 variants are Delta, Kappa and Epsilon. Delta (B.1.617.2 lineage) and Kappa (B.1.617.1 lineage) were closely associated with a huge COVID-19 increase in India during spring 2021. Delta variant has multiple mutations in the Spike protein, including P681R and L452R. Kappa variant has also genetic mutations in the Spike protein, including P681R, L452R and E484Q. Epsilon variant, first detected in California, USA, consists of two distinct lineages B.1.427 and B.1.429 in clade 20C. This variant has multiple mutations in the spike protein, including L452R. An estimated increase in transmission rate of the B.1.427/B.1.429 lineages related to circulating non- B.1.427/B.1.429 lineages was 20%.
All these variants described above show potential reduction in neutralization by some
immunotherapies and reduction of expected effects of vaccines or has been identified to cause community transmission. That is why, their appearance constitute a first-order public health problem that can have an important impact on control of the pandemic. A concern regarding the new variants is that their detection by molecular techniques (RT-PCR) could be affected.
For this reason, VIASURE SARS-CoV-2 Variant II Real Time PCR Detection Kit has been designed to allow the detection of the main mutation associated with the variant under surveillance. The test is intended for use as an aid to monitor the prevalence of genetic mutations in the S gene (P681R, L452R and E484Q) and to assist in control measures. RNA is extracted from respiratory specimens, complementary DNA (cDNA) is synthesized and amplified using RT-qPCR and detected using fluorescent reporter dye probes specific for genetic mutations in the S gene (P681R, L452R and E484Q).
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants